Circulating Organic Acid Profiles in Non-Ischaemic Cardiomyopathy: A Case–Control Study
Open Access
- 27 July 2026
- journal article
- research article
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (8) , 350
Abstract
Metabolic remodeling is increasingly recognized as a key component of cardiomyopathy, yet the circulating organic acid profile associated with this condition remains incompletely characterized. In this case–control study, we investigated differences in circulating organic acid profiles between patients with cardiomyopathy and control participants using targeted liquid chromatography–tandem mass spectrometry (LC-MS/MS). A total of 160 participants were enrolled, including 80 patients with cardiomyopathy and 80 age- and sex-comparable control participants. Circulating organic acids were quantitatively analyzed, and between-group differences were assessed using the two-sided Mann–Whitney U test with Benjamini–Hochberg false discovery rate correction; effect sizes were estimated using Cliff’s delta. Detection rates were also examined because several metabolites included values below the assay limit of detection. Sixteen metabolites remained significant after correction. Among these, 3-hydroxyisovaleric acid demonstrated the largest increase, followed by 2-oxoglutaric acid and 2-methylcitric acid. Additional elevations were observed in citric acid, malic acid, N-acetylaspartic acid, fumaric acid, and suberic acid, whereas 2-oxoadipic acid was reduced. These alterations are consistent with perturbations in mitochondrial intermediary metabolism, branched-chain amino acid catabolism, ketone body metabolism, and tricarboxylic acid cycle-related pathways. However, because comorbidities, renal function, glycemic status, and medication use differed between groups, the findings should be interpreted as phenotype-associated metabolic signals rather than cardiomyopathy-specific causal effects or validated diagnostic biomarkers. In conclusion, targeted LC-MS/MS-based organic acid profiling reveals an altered circulating metabolic pattern in cardiomyopathy, although further prospective studies with individual-level adjustment and external validation are required to determine its clinical relevance.Keywords
This publication has 22 references indexed in Scilit:
- Plasma Metabolomics Identifies Signatures that Distinguish Heart Failure with Reduced and Preserved Ejection FractionESC Heart Failure, 2025
- Towards Metabolomic-Based Precision Approaches for Classifying and Treating Heart FailureJACC: Basic To Translational Science, 2024
- Metabolomics and mitochondrial dysfunction in cardiometabolic diseaseLife Sciences, 2023
- Circulating citric acid cycle metabolites and risk of cardiovascular disease in the PREDIMED studyNutrition, Metabolism and Cardiovascular Diseases, 2023
- Branched-chain amino acids in cardiovascular diseaseNature Reviews Cardiology, 2022
- Branched-Chain Amino Acid Metabolism in the Failing HeartCardiovascular Drugs and Therapy, 2022
- Dilated cardiomyopathyNature Reviews Disease Primers, 2019
- Evidence for functional and regulatory cross-talk between the tricarboxylic acid cycle 2-oxoglutarate dehydrogenase complex and 2-oxoadipate dehydrogenase on the l-lysine, l-hydroxylysine and l-tryptophan degradation pathways from studies in vitroBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2018
- Targeted Metabolomic Profiling of Plasma and Survival in Heart Failure PatientsJACC: Heart Failure, 2017
- Targeted MetabolomicsCurrent Protocols in Molecular Biology, 2012